Top in hem/onc: Enzastaurin, financial toxicity, burnout
The FDA recently granted fast track designation to enzastaurin for the treatment of newly diagnosed glioblastoma. It was the top story in hematology/oncology last week.
Another top story was about the financial toll of parking fees at cancer treatment centers on patients and caregivers.
Read these and more top stories in hematology/oncology below:
FDA grants fast track status to enzastaurin for newly diagnosed glioblastoma
The FDA granted fast track designation to enzastaurin (DB102, Denovo Biopharma) for the treatment of patients with newly diagnosed glioblastoma, according to a press release from the agent’s manufacturer. Read more.
Parking fees at cancer treatment centers can substantially impact costs of care
Parking costs at cancer treatment centers — including those with the highest standard of care — can be a source of financial toxicity for patients and caregivers, according to a research letter published in JAMA Oncology. Read more.
Burnout on the rise among oncology physician assistants
Several studies have shown evidence among oncologists of burnout, characterized by severe emotional exhaustion, depersonalization and a low sense of personal accomplishment resulting from ongoing or extreme workplace stress. Now, a study conducted at Fox Chase Cancer Center showed oncology physician assistants also experience significant levels of burnout. Read more.
FDA panel supports approval of belantamab mafodotin for relapsed/refractory myeloma
An FDA advisory committee voted unanimously to recommend the approval of belantamab mafodotin (GSK2857916, GlaxoSmithKline) for patients with relapsed or refractory multiple myeloma, concluding the clinical benefits outweigh potential risks that include keratopathy. Read more.
New framework takes genetic testing guidelines for prostate cancer ‘a step further’
All men with metastatic prostate cancer should undergo genetic testing to better inform decisions on precision medicine or clinical trial eligibility, according to recommendations developed at a multidisciplinary consensus conference. Read more.